CAS: 2070009-58-2

Ravoxertinib hydrochloride is an investigational pharmaceutical compound, specifically a selective small molecule inhibitor. It is synthesized chemically, designed to target and inhibit specific protein kinases, particularly those associated with the ERK signaling pathway. The mode of action involves binding to these kinases, thus preventing their phosphorylation and subsequent activation. This interruption of the cellular signaling cascade can result in the suppression of tumor cell proliferation and survival. Ravoxertinib hydrochloride is primarily being explored for its therapeutic potential in the treatment of various cancers, particularly those driven by aberrant RAS-RAF-MEK-ERK pathway activation. It aims to provide a targeted approach, potentially enhancing the efficacy of cancer therapies while minimizing impacts on normal cells. Ongoing studies are focusing on its application in cancers such as melanoma and non-small cell lung cancer, where ERK pathway mutations or dysregulations are prevalent. The development and application of Ravoxertinib hydrochloride represent promising strides in the advancement of precision oncology.

GDC-0994 hydrochloride

Ravoxertinib hydrochloride is an orally bioavailable and selective inhibitor for ERK kinase activity (IC50: 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively).